X4 Pharmaceuticals, Inc. Expected to Post Q3 2024 Earnings of ($0.19) Per Share (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities research analysts at Brookline Capital Management dropped their Q3 2024 earnings per share estimates for X4 Pharmaceuticals in a research note issued on Monday, April 29th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.15). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.51) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.66) EPS and FY2025 earnings at ($0.06) EPS.

Separately, HC Wainwright lifted their price target on shares of X4 Pharmaceuticals from $3.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday.

X4 Pharmaceuticals Trading Up 6.5 %

XFOR opened at $1.15 on Thursday. The firm has a market capitalization of $193.13 million, a P/E ratio of -1.92 and a beta of 0.51. The firm’s 50 day moving average is $1.16 and its 200-day moving average is $0.93. The company has a quick ratio of 5.34, a current ratio of 5.34 and a debt-to-equity ratio of 1.07. X4 Pharmaceuticals has a 52-week low of $0.57 and a 52-week high of $2.58.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.05.

Insiders Place Their Bets

In related news, CFO Adam S. Mostafa sold 52,500 shares of X4 Pharmaceuticals stock in a transaction on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $46,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Adam S. Mostafa sold 27,721 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares in the company, valued at approximately $53,025. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam S. Mostafa sold 52,500 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $46,200.00. The disclosure for this sale can be found here. Insiders have sold 185,708 shares of company stock worth $170,428 in the last three months. 1.08% of the stock is owned by insiders.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth approximately $37,000. Barclays PLC boosted its holdings in shares of X4 Pharmaceuticals by 334.8% during the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock valued at $417,000 after acquiring an additional 294,255 shares during the period. GSA Capital Partners LLP acquired a new position in shares of X4 Pharmaceuticals during the third quarter valued at $678,000. Kingdon Capital Management L.L.C. grew its position in shares of X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after acquiring an additional 1,500,000 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after acquiring an additional 668,422 shares during the period. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.